New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
August 25, 2015
09:13 EDTAAPL, JPMOn The Fly: Pre-market Movers
Subscribe for More Information
08:43 EDTAAPLBest Buy to sell Apple Care in stores this quarter
Subscribe for More Information
07:28 EDTJPM, JPMJPMorgan upgraded to Buy from Outperform at CLSA
CLSA analyst Mike Mayo upgraded JPMorgan to Buy from Outperform with a $78 price target. Mayo said JPMorgan offers the most stable earnings of U.S. global banks for the past decade, a resilient balance sheet, and a dividend yield above the 10 year bond that implies outperformance 85% of the time historically.
07:22 EDTAAPLWells Fargo says Apple correction overdone, upgrades to Outperform
Wells Fargo analyst Maynard Um said that his fundamental stance on Apple's challenges is unchanged, but that the stock's decline of roughly 22% since mid-July is an overdone correction, prompting him to upgrade the stock to Outperform from Market Perform. Um added that Tim Cook's email regarding iPhone activation growth in China having recently accelerated gives better visibility to the September quarter and that Apple's third party manufacturing and component commitments suggest upside potential to the company's revenue guidance. The firm has a $125-$135 price target range on Apple shares.
06:19 EDTAAPLApple upgraded to Outperform from Market Perform at Wells Fargo
August 24, 2015
18:02 EDTJPMS&P 500 enters correction territory amid global growth concerns
Subscribe for More Information
16:23 EDTAAPLOn The Fly: Top stock stories for Monday
Subscribe for More Information
16:00 EDTAAPLOptions Update; August 24, 2015
Subscribe for More Information
14:54 EDTAAPLApple CEO may have broken SEC rules with email, MarketWatch says
Subscribe for More Information
13:42 EDTAAPLApple goes negative on the session, levels to watch
Subscribe for More Information
13:15 EDTNVSFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
12:17 EDTAAPLOn The Fly: Top stock stories at midday
Subscribe for More Information
12:11 EDTNVSNovartis announces FDA approves expanded use for Promacta
Subscribe for More Information
11:46 EDTAAPLApple turns positive on the session
Subscribe for More Information
11:05 EDTAAPLStocks with call strike movement; FB AAPL
Subscribe for More Information
10:23 EDTAAPLApple continues to edge up off earlier lows
Subscribe for More Information
10:12 EDTAAPLApple China concerns 'way overblown,' says Cantor
Cantor Fitzgerald analyst Brian White attributes the slide in Apple shares to growing fears regarding China, but White believes those concerns have been "way overblown" and have pushed the stock to a "severely depressed" valuation. Even if EPS estimates for calendar year 2016 are only 50% of the firm's current projection, the stock is trading at a multiple of "just 14.5x" that projection, notes White, who "highly" doubts that even a global recession would drive Apple's results to slide that far. White reiterates a Buy rating and $195 price target on shares of Apple, which are down 2% to $103.65 in early trading this morning.
09:45 EDTMPCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:44 EDTAAPLApple drops sharply, cuts losses
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use